20/20 BioLabs Reports Strong 2025 Financials, Nasdaq Listing & Growth
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
20/20 BioLabs Reports Strong Full Year 2025 Financial Results and Significant Operational Progress
Gaithersburg, MD - 20/20 BioLabs, Inc. (Nasdaq: AIDX), a pioneer in AI-powered laboratory-based blood tests for early disease detection, announced its full year financial results for 2025 and provided an update on significant operational progress extending into early 2026. The company reported strong financial improvements and key strategic advancements, including its recent listing on Nasdaq and a substantial private placement.
... Read on — Members only
About 20/20 Biolabs, Inc.
Health
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.